RJA
GYRE icon

Raymond James & Associates’s Gyre Therapeutics GYRE Stock Holding History

Raymond James & Associates’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-860
Closed -$6.22K – 3872
2023
Q3 		$6.22K Hold
860
– – ﹤0.01% 3774
2023
Q2 		$4.54K Sell
860
-3,333
-79% -$11.9K ﹤0.01% 3825
2023
Q1 		$13K Sell
4,193
-143
-3% -$543 ﹤0.01% 3823
2022
Q4 		$17.2K Sell
4,336
-1,813
-29% -$7.4K ﹤0.01% 3809
2022
Q3 		$23K Buy
6,149
+1,816
+42% +$23.1K ﹤0.01% 3786
2022
Q2 		$58K Hold
4,333
– – ﹤0.01% 3772
2022
Q1 		$21K Sell
4,333
-40
-0.9% -$198 ﹤0.01% 3999
2021
Q4 		$30K Sell
4,373
-12,901
-75% -$221K ﹤0.01% 3994
2021
Q3 		$532K Sell
17,274
-743
-4% -$24.4K ﹤0.01% 3018
2021
Q2 		$585K Buy
18,017
+990
+6% +$34K ﹤0.01% 2974
2021
Q1 		$644K Sell
17,027
-5,495
-24% -$251K ﹤0.01% 2818
2020
Q4 		$1.07M Buy
22,522
+12,762
+131% +$553K ﹤0.01% 2302
2020
Q3 		$315K Buy
9,760
+1,866
+24% +$73K ﹤0.01% 2926
2020
Q2 		$348K Buy
+7,894
New +$371K ﹤0.01% 2835
2018
Q1 		– Sell
-5,719
Closed -$585K – 3507
2017
Q4 		$585K Buy
+5,719
New +$292K ﹤0.01% 2432

Other funds holding GYRE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Raymond James & Associates's GYRE Position: Q4 2023 in Review

Raymond James & Associates sold out of Gyre Therapeutics (GYRE) in Q4 2023, closing a stake of 860 shares — an estimated $6.22K sold.

Raymond James & Associates first reported a position in GYRE in Q4 2017 and held it in 15 quarters. The position peaked at $1.07M in Q4 2020. 16 funds tracked by Wall St. Rank hold GYRE as of Q4 2023.

  • Raymond James & Associates reported no remaining Gyre Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Raymond James & Associates sold 860 Gyre Therapeutics shares in Q4 2023, an estimated $6.22K.
  • Raymond James & Associates first reported a position in Gyre Therapeutics in Q4 2017 and held it in 15 quarters.
  • Raymond James & Associates's Gyre Therapeutics position peaked at $1.07M in Q4 2020.
  • 16 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2023.

Based on Raymond James & Associates's 13F filing for Q4 2023, filed 16 Jan 2024.